-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mindray Orthopedics, with a large layout of 4.
5 billion, has another big move!
5 billion, has another big move!
Revenue grew 74% ! Orthopedic implants to be mass-produced next year
Recently, Wuhan Mindray, a wholly-owned subsidiary of Mindray, said that after two years of intelligent transformation, the research and development cycle of new products of Wuhan Mindray Technology has been shortened by 20%, and last year's operating income increased by 74% compared with 2020
.
.
However, it also revealed that the current production capacity of the company has reached its limit and it is difficult to meet the needs of business expansion
.
.
At present, Mindray has invested 2 billion yuan in the Optics Valley production base project.
The project is constructed for the production and operation of medical equipment and biological raw materials.
The main content is the manufacture of orthopedic implants, minimally invasive surgical equipment and corresponding supporting equipment
.
The project is constructed for the production and operation of medical equipment and biological raw materials.
The main content is the manufacture of orthopedic implants, minimally invasive surgical equipment and corresponding supporting equipment
.
According to reports, the construction of the production base has now completed all the preparatory work before the official construction
.
It is planned that the first phase of the plant will be put into use in September this year, and the mass production of orthopedic products will begin in early 2023
.
.
It is planned that the first phase of the plant will be put into use in September this year, and the mass production of orthopedic products will begin in early 2023
.
Wuhan Mindray currently produces more than 300 orthopedic implants with more than 3,000 specifications
.
It produces orthopedic implants down to the micron scale
.
For example, "the wear amount of 1 million times of ceramic and highly cross-linked lining is about 3 mg, which is very good to avoid bone resorption caused by fine particles"
.
Hip joint products are also at a high level in China in terms of the long-term wear of the joint ball head and the automatic introduction performance of the acetabular cup installation
.
.
It produces orthopedic implants down to the micron scale
.
For example, "the wear amount of 1 million times of ceramic and highly cross-linked lining is about 3 mg, which is very good to avoid bone resorption caused by fine particles"
.
Hip joint products are also at a high level in China in terms of the long-term wear of the joint ball head and the automatic introduction performance of the acetabular cup installation
.
It is reported that Wuhan Mindray has established cooperation with Tongji Hospital, Wuhan University Zhongnan Hospital, Union Hospital and Huazhong University of Science and Technology, and has carried out in-depth research on the optimization of clinical pain points during orthopedic surgery, the development of orthopedic biomaterials, and the development of orthopedic precision machining technology.
cooperation
.
cooperation
.
It is worth noting that in the national procurement of artificial joints (including hip joints and knee joints) carried out last year, 44 enterprises were selected.
Among all the international and domestic enterprises that won bids for Shenzhen Mindray joint products, the proportion of hospital applications entered the top ten.
become the main supplier
.
Among all the international and domestic enterprises that won bids for Shenzhen Mindray joint products, the proportion of hospital applications entered the top ten.
become the main supplier
.
4.
5 billion to enter orthopaedics! Targeting high-margin markets
5 billion to enter orthopaedics! Targeting high-margin markets
Mindray has steadily deployed orthopaedics for a long time
.
.
As early as 2012, Mindray fully acquired "De Iberia", which has a rich orthopaedic product line, covering joints, trauma, spine, external fixation, closed negative pressure drainage materials and other orthopedic implants and consumables
.
.
Founded in 1999, Delia Bair is headquartered in Wuhan.
It has established sales and logistics service platforms in more than 40 cities across the country, serving more than 2,000 medical institutions across the country.
It has established sales and logistics service platforms in more than 40 cities across the country, serving more than 2,000 medical institutions across the country.
Eight years later, in 2020, Mindray Medical's Wuhan base will start construction.
The project has a total investment of 4.
5 billion yuan.
After completion, it will become Mindray Medical's second global headquarters base
.
The construction content of the project includes the manufacture of orthopedic implants and surgical treatment equipment, and the manufacture of minimally invasive surgical equipment
.
The project has a total investment of 4.
5 billion yuan.
After completion, it will become Mindray Medical's second global headquarters base
.
The construction content of the project includes the manufacture of orthopedic implants and surgical treatment equipment, and the manufacture of minimally invasive surgical equipment
.
This move means that Mindray has officially entered the field of orthopedics
.
.
Combined with the display on Mindray's official website, Mindray is entering orthopedics in an all-round way, rather than a single field
.
.
As one of the four major fields of medical devices
in the world, orthopedics will be a high-growth and high-increment market in China in the future .
in the world, orthopedics will be a high-growth and high-increment market in China in the future .
According to public data, in terms of market penetration, the market penetration rates of trauma, spine and joints in China are 4.
9%, 1.
5% and 0.
6%, respectively, and 66%, 38%, and 43% in the United States
.
According to the prediction of industry investors, orthopedics is one of the tracks that can generate 5 times the stock in the future
.
9%, 1.
5% and 0.
6%, respectively, and 66%, 38%, and 43% in the United States
.
According to the prediction of industry investors, orthopedics is one of the tracks that can generate 5 times the stock in the future
.
In addition, factors such as the aging population drive the accelerated expansion of the orthopedic medical industry, and the purchase of orthopedic consumables and other favorable factors that further promote the import substitution of domestic brands are all driving Mindray Medical to accelerate the layout of this gross profit rate generally as high as 80%-90% of the track.
important reason
.
important reason
.
4 New Seed Businesses! Mindray Medical's Strategic Layout
How big is the market for Mindray's business? According to the statistics of Mindray Medical, the accessible market space corresponding to the three traditional production lines and four high-potential businesses that Mindray has deployed is 120 billion yuan and 710 billion yuan domestically and internationally
.
.
In 2020, the company's domestic and international revenue will be 11.
1 billion yuan and 9.
9 billion yuan respectively, of which the international market share is currently only in the low single digits.
Therefore, there is still huge room for growth in the future of the deployed business, especially the international market
.
1 billion yuan and 9.
9 billion yuan respectively, of which the international market share is currently only in the low single digits.
Therefore, there is still huge room for growth in the future of the deployed business, especially the international market
.
Internationally, Mindray Medical believes that in the long run, larger market space and more growth opportunities come from overseas markets, especially emerging markets
.
Based on the marketing network coverage established in emerging market countries and the relevant experience accumulated in China, the growth of emerging market countries will accelerate and is expected to catch up with China
.
.
Based on the marketing network coverage established in emerging market countries and the relevant experience accumulated in China, the growth of emerging market countries will accelerate and is expected to catch up with China
.
The old branch has, what is the new bud?
Mindray pointed out that the selection of new business areas will be based on the following three considerations: there are certain technical thresholds, which can give full play to the company's advantages in R&D; international expansion, effectively utilizing the advantages of the global business platform and maximizing the efficiency of R&D expenses; It can serve the critical, emergency, minimally invasive surgery, inspection, ultrasound and other ecosystems that the company is striving to build
.
.
In addition to the three main businesses of life information and support, in vitro diagnostic business and medical imaging, it also continuously invests in the four seed businesses of animal medicine, minimally invasive surgery, orthopedics and AED
.
.
Mindray Medical has responded to investors that the four seed businesses are expected to maintain rapid development in the next three years
.
Based on the optimism about the development prospects of these four seed businesses, the revenue volume targets of these four businesses in the next three years have been raised
.
.
Based on the optimism about the development prospects of these four seed businesses, the revenue volume targets of these four businesses in the next three years have been raised
.
Mindray said that although orthopedics is facing centralized procurement, it is more of an opportunity for the company.
While improving the technical level and product quality of orthopedics, how to expand automated production and reduce costs is the key
.
While improving the technical level and product quality of orthopedics, how to expand automated production and reduce costs is the key
.
In addition to the large-scale construction of a production base in Wuhan, Mindray also plans to build a Mindray Dangshan production base in Dangshan County, Anhui Province, build an intelligent and information-based factory, and gradually undertake some orthopedic instruments and machining production, reducing the cost of orthopedic business
.
.
Mindray Orthopedics, with a large layout of 4.
5 billion, has another big move!
5 billion, has another big move!
Revenue grew 74% ! Orthopedic implants to be mass-produced next year
Recently, Wuhan Mindray, a wholly-owned subsidiary of Mindray, said that after two years of intelligent transformation, the research and development cycle of new products of Wuhan Mindray Technology has been shortened by 20%, and last year's operating income increased by 74% compared with 2020
.
.
However, it also revealed that the current production capacity of the company has reached its limit and it is difficult to meet the needs of business expansion
.
.
At present, Mindray has invested 2 billion yuan in the Optics Valley production base project.
The project is constructed for the production and operation of medical equipment and biological raw materials.
The main content is the manufacture of orthopedic implants, minimally invasive surgical equipment and corresponding supporting equipment
.
The project is constructed for the production and operation of medical equipment and biological raw materials.
The main content is the manufacture of orthopedic implants, minimally invasive surgical equipment and corresponding supporting equipment
.
According to reports, the construction of the production base has now completed all the preparatory work before the official construction
.
It is planned that the first phase of the plant will be put into use in September this year, and the mass production of orthopedic products will begin in early 2023
.
.
It is planned that the first phase of the plant will be put into use in September this year, and the mass production of orthopedic products will begin in early 2023
.
Wuhan Mindray currently produces more than 300 orthopedic implants with more than 3,000 specifications
.
It produces orthopedic implants down to the micron scale
.
For example, "the wear amount of 1 million times of ceramic and highly cross-linked lining is about 3 mg, which is very good to avoid bone resorption caused by fine particles"
.
Hip joint products are also at a high level in China in terms of the long-term wear of the joint ball head and the automatic introduction performance of the acetabular cup installation
.
.
It produces orthopedic implants down to the micron scale
.
For example, "the wear amount of 1 million times of ceramic and highly cross-linked lining is about 3 mg, which is very good to avoid bone resorption caused by fine particles"
.
Hip joint products are also at a high level in China in terms of the long-term wear of the joint ball head and the automatic introduction performance of the acetabular cup installation
.
It is reported that Wuhan Mindray has established cooperation with Tongji Hospital, Wuhan University Zhongnan Hospital, Union Hospital and Huazhong University of Science and Technology, and has carried out in-depth research on the optimization of clinical pain points during orthopedic surgery, the development of orthopedic biomaterials, and the development of orthopedic precision machining technology.
cooperation
.
cooperation
.
It is worth noting that in the national procurement of artificial joints (including hip joints and knee joints) carried out last year, 44 enterprises were selected.
Among all the international and domestic enterprises that won bids for Shenzhen Mindray joint products, the proportion of hospital applications entered the top ten.
become the main supplier
.
Among all the international and domestic enterprises that won bids for Shenzhen Mindray joint products, the proportion of hospital applications entered the top ten.
become the main supplier
.
4.
5 billion to enter orthopaedics! Targeting high-margin markets
5 billion to enter orthopaedics! Targeting high-margin markets
Mindray has steadily deployed orthopaedics for a long time
.
.
As early as 2012, Mindray fully acquired "De Iberia", which has a rich orthopaedic product line, covering joints, trauma, spine, external fixation, closed negative pressure drainage materials and other orthopedic implants and consumables
.
.
Founded in 1999, Delia Bair is headquartered in Wuhan.
It has established sales and logistics service platforms in more than 40 cities across the country, serving more than 2,000 medical institutions across the country.
It has established sales and logistics service platforms in more than 40 cities across the country, serving more than 2,000 medical institutions across the country.
Eight years later, in 2020, Mindray Medical's Wuhan base will start construction.
The project has a total investment of 4.
5 billion yuan.
After completion, it will become Mindray Medical's second global headquarters base
.
The construction content of the project includes the manufacture of orthopedic implants and surgical treatment equipment, and the manufacture of minimally invasive surgical equipment
.
The project has a total investment of 4.
5 billion yuan.
After completion, it will become Mindray Medical's second global headquarters base
.
The construction content of the project includes the manufacture of orthopedic implants and surgical treatment equipment, and the manufacture of minimally invasive surgical equipment
.
This move means that Mindray has officially entered the field of orthopedics
.
.
Combined with the display on Mindray's official website, Mindray is entering orthopedics in an all-round way, rather than a single field
.
.
As one of the four major fields of medical devices
in the world, orthopedics will be a high-growth and high-increment market in China in the future .
in the world, orthopedics will be a high-growth and high-increment market in China in the future .
According to public data, in terms of market penetration, the market penetration rates of trauma, spine and joints in China are 4.
9%, 1.
5% and 0.
6%, respectively, and 66%, 38%, and 43% in the United States
.
According to the prediction of industry investors, orthopedics is one of the tracks that can generate 5 times the stock in the future
.
9%, 1.
5% and 0.
6%, respectively, and 66%, 38%, and 43% in the United States
.
According to the prediction of industry investors, orthopedics is one of the tracks that can generate 5 times the stock in the future
.
In addition, factors such as the aging population drive the accelerated expansion of the orthopedic medical industry, and the purchase of orthopedic consumables and other favorable factors that further promote the import substitution of domestic brands are all driving Mindray Medical to accelerate the layout of this gross profit rate generally as high as 80%-90% of the track.
important reason
.
important reason
.
4 New Seed Businesses! Mindray Medical's Strategic Layout
How big is the market for Mindray's business? According to the statistics of Mindray Medical, the accessible market space corresponding to the three traditional production lines and four high-potential businesses that Mindray has deployed is 120 billion yuan and 710 billion yuan domestically and internationally
.
.
In 2020, the company's domestic and international revenue will be 11.
1 billion yuan and 9.
9 billion yuan respectively, of which the international market share is currently only in the low single digits.
Therefore, there is still huge room for growth in the future of the deployed business, especially the international market
.
1 billion yuan and 9.
9 billion yuan respectively, of which the international market share is currently only in the low single digits.
Therefore, there is still huge room for growth in the future of the deployed business, especially the international market
.
Internationally, Mindray Medical believes that in the long run, larger market space and more growth opportunities come from overseas markets, especially emerging markets
.
Based on the marketing network coverage established in emerging market countries and the relevant experience accumulated in China, the growth of emerging market countries will accelerate and is expected to catch up with China
.
.
Based on the marketing network coverage established in emerging market countries and the relevant experience accumulated in China, the growth of emerging market countries will accelerate and is expected to catch up with China
.
The old branch has, what is the new bud?
Mindray pointed out that the selection of new business areas will be based on the following three considerations: there are certain technical thresholds, which can give full play to the company's advantages in R&D; international expansion, effectively utilizing the advantages of the global business platform and maximizing the efficiency of R&D expenses; It can serve the critical, emergency, minimally invasive surgery, inspection, ultrasound and other ecosystems that the company is striving to build
.
.
In addition to the three main businesses of life information and support, in vitro diagnostic business and medical imaging, it also continuously invests in the four seed businesses of animal medicine, minimally invasive surgery, orthopedics and AED
.
.
Mindray Medical has responded to investors that the four seed businesses are expected to maintain rapid development in the next three years
.
Based on the optimism about the development prospects of these four seed businesses, the revenue volume targets of these four businesses in the next three years have been raised
.
.
Based on the optimism about the development prospects of these four seed businesses, the revenue volume targets of these four businesses in the next three years have been raised
.
Mindray said that although orthopedics is facing centralized procurement, it is more of an opportunity for the company.
While improving the technical level and product quality of orthopedics, how to expand automated production and reduce costs is the key
.
While improving the technical level and product quality of orthopedics, how to expand automated production and reduce costs is the key
.
In addition to the large-scale construction of a production base in Wuhan, Mindray also plans to build a Mindray Dangshan production base in Dangshan County, Anhui Province, build an intelligent and information-based factory, and gradually undertake some orthopedic instruments and machining production, reducing the cost of orthopedic business
.
.
Mindray Orthopedics, with a large layout of 4.
5 billion, has another big move!
5 billion, has another big move!
Revenue grew 74% ! Orthopedic implants to be mass-produced next year
Revenue grew 74% ! Orthopedic implants to be mass-produced next year Recently, Wuhan Mindray, a wholly-owned subsidiary of Mindray, said that after two years of intelligent transformation, the research and development cycle of new products of Wuhan Mindray Technology has been shortened by 20%, and last year's operating income increased by 74% compared with 2020
.
.
However, it also revealed that the current production capacity of the company has reached its limit and it is difficult to meet the needs of business expansion
.
.
At present, Mindray has invested 2 billion yuan in the Optics Valley production base project.
The project is constructed for the production and operation of medical equipment and biological raw materials.
The main content is the manufacture of orthopedic implants, minimally invasive surgical equipment and corresponding supporting equipment
.
The project is constructed for the production and operation of medical equipment and biological raw materials.
The main content is the manufacture of orthopedic implants, minimally invasive surgical equipment and corresponding supporting equipment
.
According to reports, the construction of the production base has now completed all the preparatory work before the official construction
.
It is planned that the first phase of the plant will be put into use in September this year, and the mass production of orthopedic products will begin in early 2023
.
.
It is planned that the first phase of the plant will be put into use in September this year, and the mass production of orthopedic products will begin in early 2023
.
Wuhan Mindray currently produces more than 300 orthopedic implants with more than 3,000 specifications
.
It produces orthopedic implants down to the micron scale
.
For example, "the wear amount of 1 million times of ceramic and highly cross-linked lining is about 3 mg, which is very good to avoid bone resorption caused by fine particles"
.
Hip joint products are also at a high level in China in terms of the long-term wear of the joint ball head and the automatic introduction performance of the acetabular cup installation
.
.
It produces orthopedic implants down to the micron scale
.
For example, "the wear amount of 1 million times of ceramic and highly cross-linked lining is about 3 mg, which is very good to avoid bone resorption caused by fine particles"
.
Hip joint products are also at a high level in China in terms of the long-term wear of the joint ball head and the automatic introduction performance of the acetabular cup installation
.
It is reported that Wuhan Mindray has established cooperation with Tongji Hospital, Wuhan University Zhongnan Hospital, Union Hospital and Huazhong University of Science and Technology, and has carried out in-depth research on the optimization of clinical pain points during orthopedic surgery, the development of orthopedic biomaterials, and the development of orthopedic precision machining technology.
cooperation
.
cooperation
.
It is worth noting that in the national procurement of artificial joints (including hip joints and knee joints) carried out last year, 44 enterprises were selected.
Among all the international and domestic enterprises that won bids for Shenzhen Mindray joint products, the proportion of hospital applications entered the top ten.
become the main supplier
.
Enterprise Enterprise Enterprise Hospital Hospital HospitalAmong all the international and domestic enterprises that won bids for Shenzhen Mindray joint products, the proportion of hospital applications entered the top ten.
become the main supplier
.
4.
5 billion to enter orthopaedics! Targeting high-margin markets
4. 5 billion to enter orthopaedics! Targeting high-margin markets
5 billion to enter orthopaedics! Targeting high-margin markets
Mindray has steadily deployed orthopaedics for a long time
.
.
As early as 2012, Mindray fully acquired "De Iberia", which has a rich orthopaedic product line, covering joints, trauma, spine, external fixation, closed negative pressure drainage materials and other orthopedic implants and consumables
.
.
Founded in 1999, Delia Bair is headquartered in Wuhan.
It has established sales and logistics service platforms in more than 40 cities across the country, serving more than 2,000 medical institutions across the country.
It has established sales and logistics service platforms in more than 40 cities across the country, serving more than 2,000 medical institutions across the country.
Eight years later, in 2020, Mindray Medical's Wuhan base will start construction.
The project has a total investment of 4.
5 billion yuan.
After completion, it will become Mindray Medical's second global headquarters base
.
The construction content of the project includes the manufacture of orthopedic implants and surgical treatment equipment, and the manufacture of minimally invasive surgical equipment
.
The project has a total investment of 4.
5 billion yuan.
After completion, it will become Mindray Medical's second global headquarters base
.
The construction content of the project includes the manufacture of orthopedic implants and surgical treatment equipment, and the manufacture of minimally invasive surgical equipment
.
This move means that Mindray has officially entered the field of orthopedics
.
.
Combined with the display on Mindray's official website, Mindray is entering orthopedics in an all-round way, rather than a single field
.
.
As one of the four major fields of medical devices
in the world, orthopedics will be a high-growth and high-increment market in China in the future .
medical device medical device medical devicein the world, orthopedics will be a high-growth and high-increment market in China in the future .
According to public data, in terms of market penetration, the market penetration rates of trauma, spine and joints in China are 4.
9%, 1.
5% and 0.
6%, respectively, and 66%, 38%, and 43% in the United States
.
According to the prediction of industry investors, orthopedics is one of the tracks that can generate 5 times the stock in the future
.
9%, 1.
5% and 0.
6%, respectively, and 66%, 38%, and 43% in the United States
.
According to the prediction of industry investors, orthopedics is one of the tracks that can generate 5 times the stock in the future
.
In addition, factors such as the aging population drive the accelerated expansion of the orthopedic medical industry, and the purchase of orthopedic consumables and other favorable factors that further promote the import substitution of domestic brands are all driving Mindray Medical to accelerate the layout of this gross profit rate generally as high as 80%-90% of the track.
important reason
.
purchase purchase purchaseimportant reason
.
4 New Seed Businesses! Mindray Medical's Strategic Layout
4 New Seed Businesses! Mindray Medical's Strategic Layout How big is the market for Mindray's business? According to the statistics of Mindray Medical, the accessible market space corresponding to the three traditional production lines and four high-potential businesses that Mindray has deployed is 120 billion yuan and 710 billion yuan domestically and internationally
.
.
In 2020, the company's domestic and international revenue will be 11.
1 billion yuan and 9.
9 billion yuan respectively, of which the international market share is currently only in the low single digits.
Therefore, there is still huge room for growth in the future of the deployed business, especially the international market
.
1 billion yuan and 9.
9 billion yuan respectively, of which the international market share is currently only in the low single digits.
Therefore, there is still huge room for growth in the future of the deployed business, especially the international market
.
Internationally, Mindray Medical believes that in the long run, larger market space and more growth opportunities come from overseas markets, especially emerging markets
.
Based on the marketing network coverage established in emerging market countries and the relevant experience accumulated in China, the growth of emerging market countries will accelerate and is expected to catch up with China
.
.
Based on the marketing network coverage established in emerging market countries and the relevant experience accumulated in China, the growth of emerging market countries will accelerate and is expected to catch up with China
.
The old branch has, what is the new bud?
The old branch has, what is the new bud? Mindray pointed out that the selection of new business areas will be based on the following three considerations: there are certain technical thresholds, which can give full play to the company's advantages in R&D; international expansion, effectively utilizing the advantages of the global business platform and maximizing the efficiency of R&D expenses; It can serve the critical, emergency, minimally invasive surgery, inspection, ultrasound and other ecosystems that the company is striving to build
.
.
In addition to the three main businesses of life information and support, in vitro diagnostic business and medical imaging, it also continuously invests in the four seed businesses of animal medicine, minimally invasive surgery, orthopedics and AED
.
.
Mindray Medical has responded to investors that the four seed businesses are expected to maintain rapid development in the next three years
.
Based on the optimism about the development prospects of these four seed businesses, the revenue volume targets of these four businesses in the next three years have been raised
.
.
Based on the optimism about the development prospects of these four seed businesses, the revenue volume targets of these four businesses in the next three years have been raised
.
Mindray said that although orthopedics is facing centralized procurement, it is more of an opportunity for the company.
While improving the technical level and product quality of orthopedics, how to expand automated production and reduce costs is the key
.
product quality product quality product qualityWhile improving the technical level and product quality of orthopedics, how to expand automated production and reduce costs is the key
.
In addition to the large-scale construction of a production base in Wuhan, Mindray also plans to build a Mindray Dangshan production base in Dangshan County, Anhui Province, build an intelligent and information-based factory, and gradually undertake some orthopedic instruments and machining production, reducing the cost of orthopedic business
.
.
